Filing Flows › Companies › Ardent Health › Timeline
Ardent Health stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+19.6% to $17.30
Ardent Health (ARDT) stock rose 20% over the last 252 sessions, to $17.30. On the way it reported 5 quarters, its insiders filed 2 open-market trades and 4 Form 144 notices of planned sales, and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 4, 2026 | Earnings | Earnings: beat the EPS estimate by 55.0% | +10.4% (+8.7% vs SPY) | — | — |
| Oct 23, 2026 | 8-K | Directors and officers: departures, appointments, pay | −0.7% (−1.4% vs SPY) | −2.0% (−1.4% vs SPY) | — |
| Aug 27, 2026 | Form 144 | Form 144: Martin Bonick plans to sell $398K | −2.2% (−2.8% vs SPY) | −2.9% (−2.8% vs SPY) | −6.4% (−7.3% vs SPY) |
| Aug 25, 2026 | Form 144 | Form 144: Martin Bonick plans to sell $401K | +0.4% (+0.1% vs SPY) | −3.9% (−4.4% vs SPY) | −5.6% (−6.4% vs SPY) |
| Aug 20, 2026 | Form 144 | Form 144: Martin Bonick plans to sell $377K | −1.3% (−0.5% vs SPY) | +5.6% (+6.0% vs SPY) | −1.3% (−0.6% vs SPY) |
| Aug 18, 2026 | Form 144 | Form 144: Martin Bonick plans to sell $393K | +0.4% (+1.1% vs SPY) | +3.2% (+4.4% vs SPY) | −1.6% (+0.9% vs SPY) |
| Aug 4, 2026 | Earnings | Earnings: beat the EPS estimate by 43.9% | 0.0% (−1.8% vs SPY) | +2.8% (+0.8% vs SPY) | +1.7% (+1.2% vs SPY) |
| Jun 30, 2026 | 8-K | Directors and officers: departures, appointments, pay | +2.9% (+3.0% vs SPY) | +3.1% (+3.3% vs SPY) | +8.7% (+9.3% vs SPY) |
| Jun 5, 2026 | Insider buy | Lumsdaine Alfred bought $88K | +0.9% (+3.5% vs SPY) | +11.7% (+14.3% vs SPY) | +23.0% (+24.0% vs SPY) |
| Jun 5, 2026 | Insider buy | DeMichiei Robert bought $98K | +0.9% (+3.5% vs SPY) | +11.7% (+14.3% vs SPY) | +23.0% (+24.0% vs SPY) |
| Jun 2, 2026 | 8-K | Directors and officers: departures, appointments, pay | −16.9% (−16.2% vs SPY) | +1.5% (+4.5% vs SPY) | +14.9% (+16.6% vs SPY) |
| May 5, 2026 | Earnings | Earnings: beat the EPS estimate by 68.2% | +1.5% (+0.7% vs SPY) | −0.3% (−3.2% vs SPY) | −24.3% (−29.2% vs SPY) |
| Mar 27, 2026 | 8-K | Directors and officers: departures, appointments, pay | −3.9% (−3.6% vs SPY) | +4.1% (+0.2% vs SPY) | +12.3% (+0.7% vs SPY) |
| Mar 4, 2026 | Earnings | Earnings: beat the EPS estimate by 4.5% | +2.4% (+1.7% vs SPY) | −4.0% (−3.6% vs SPY) | −8.2% (−4.7% vs SPY) |
| Nov 12, 2025 | Earnings | Earnings: beat the EPS estimate by 95.9% | 0.0% (−0.1% vs SPY) | −47.9% (−44.5% vs SPY) | −47.6% (−48.5% vs SPY) |
Insiders’ record here
In the year on the chart, Ardent Health's insiders reported 2 open-market buys ($186K) and 0 sales ($0). Of the 2 old enough to score, 2 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was +21.3% and after a sale —.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Ardent Health: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.